Montreal Heart Institute, Montreal, Canada.
Université de Montréal Beaulieu-Saucier Pharmacogenomics Centre, Montreal, Canada.
Cancer Epidemiol Biomarkers Prev. 2023 Jun 1;32(6):776-783. doi: 10.1158/1055-9965.EPI-22-1290.
Cancer survivors are at an increased risk of cardiovascular disease (CVD) compared with the general population. We sought to evaluate the impact of mosaic chromosomal alterations (mCA) on death of CVD causes, coronary artery disease (CAD) causes, and of any cause in patients with a cancer diagnosis.
The study was a prospective cohort analysis of 48,919 UK Biobank participants with a cancer diagnosis. mCAs were characterized using DNA genotyping array intensity data and long-range chromosomal phase inference. Multivariable Cox regression models were used to ascertain the associations of mCAs. Exploratory endpoints included various incident cardiovascular phenotypes.
Overall, 10,070 individuals (20.6%) carried ≥ 1 mCA clone. In adjusted analyses, mCA was associated with an increased risk of death of CAD causes [HR, 1.37; 95% confidence interval (CI), 1.09-1.71; P = 0.006]. In sub-analyses, we found that carriers of mCAs diagnosed with kidney cancer had an increased risk of death of CVD causes (HR, 2.03; 95% CI, 1.11-3.72; P = 0.022) and CAD causes (HR, 3.57; 95% CI, 1.44-8.84; P = 0.006). Women diagnosed with breast cancer who carried a mCA also had a higher risk of death of CAD causes (HR, 2.46; 95% CI, 1.23-4.92; P = 0.011).
Among cancer survivors, carriers of any mCA are at an increased risk of CAD death compared with noncarriers. Mechanistic studies should be considered to better ascertain the biological mechanisms underneath the observed associations between mCAs and cardiovascular events for specific cancer types.
There may be clinical relevance in considering mCAs in patients diagnosed with cancer and undergoing treatment.
与一般人群相比,癌症幸存者患心血管疾病(CVD)的风险增加。我们旨在评估镶嵌染色体改变(mCA)对癌症患者 CVD 死因、冠心病(CAD)死因和任何原因死亡的影响。
本研究是对英国生物库 48919 名癌症患者进行的前瞻性队列分析。使用 DNA 基因分型阵列强度数据和长程染色体相位推断来描述 mCAs。多变量 Cox 回归模型用于确定 mCAs 的关联。探索性终点包括各种心血管疾病的发病表型。
总体而言,有 10070 人(20.6%)携带≥1 个 mCA 克隆。在调整分析中,mCA 与 CAD 死因死亡风险增加相关[HR,1.37;95%置信区间(CI),1.09-1.71;P = 0.006]。在亚分析中,我们发现患有肾癌的 mCA 携带者 CVD 死因(HR,2.03;95%CI,1.11-3.72;P = 0.022)和 CAD 死因(HR,3.57;95%CI,1.44-8.84;P = 0.006)的死亡风险增加。携带 mCA 的乳腺癌女性也有更高的 CAD 死因风险(HR,2.46;95%CI,1.23-4.92;P = 0.011)。
在癌症幸存者中,与非携带者相比,任何 mCA 的携带者患 CAD 死亡的风险更高。应考虑进行机制研究,以更好地确定观察到的 mCA 与特定癌症类型的心血管事件之间的生物学机制。
在接受治疗的癌症诊断患者中考虑 mCAs 可能具有临床意义。